Complete atrioventricular block
|
0.100 |
Biomarker
|
disease |
BEFREE |
The response to lamivudine therapy shares with IFN a rapid decline in ALT accompanied by an improvement in histology; at variance with IFN, in HBeAg-positive chronic hepatitis B (CHB) there is delayed seroconversion to anti-HBe which accumulates over time, the switch to anti-HBs is more rare and in the long-term, the activity of the drug is abolished by the emergence of viral mutations (YMDD-motif mutants) that may rekindle the disease.
|
14521491 |
2003 |
Complete atrioventricular block
|
0.100 |
Biomarker
|
disease |
BEFREE |
Chronic hepatitis B (CHB) patients with advanced fibrosis are often not considered for treatment with peginterferon (PEG-IFN) because IFN therapy may precipitate immunological flares, potentially inducing hepatic decompensation.
|
17604363 |
2007 |
Complete atrioventricular block
|
0.100 |
Biomarker
|
disease |
BEFREE |
The expression levels of STAT-1 and APOBEC3G in the liver of CHB patients with a complete response to IFN-α are significantly higher than that of the patients with non-response to IFN-α treatment.
|
20957108 |
2010 |
Complete atrioventricular block
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Expression of IFN-α/βR-2 in monocytes can be used as a predictable parameter to evaluate the effect of IFN-α treatment in CHB patients.
|
21445562 |
2011 |
Complete atrioventricular block
|
0.100 |
Biomarker
|
disease |
BEFREE |
On-treatment HBsAg decline during PEG-IFN therapy for HBeAg-positive CHB depends upon HBV genotype.
|
22267464 |
2012 |
Complete atrioventricular block
|
0.100 |
Biomarker
|
disease |
BEFREE |
Because of these features, new therapeutic trials based upon a combination of PEG-IFN and third generation NUC such as entecavir and tenofovir, in both naïve and NUC-exposed patients, are ongoing to further increase the rates of HBsAg seroclearance, which remains the 'ideal end-point' in all HBeAg-negative CHB subjects.
|
23286860 |
2013 |
Complete atrioventricular block
|
0.100 |
Biomarker
|
disease |
BEFREE |
HBsAg is a strong predictor of response to PEG-IFN in HBeAg-positive CHB.
|
23553752 |
2013 |
Complete atrioventricular block
|
0.100 |
Biomarker
|
disease |
BEFREE |
Extended treatment with PEG IFNα-2a with lamivudine or adefovir for 96 weeks is a promising strategy to achieve high rates of sustainable HBeAg and HBsAg seroconversion and HBV DNA suppression in patients with HBeAg-positive CHB.
|
23615131 |
2013 |
Complete atrioventricular block
|
0.100 |
Biomarker
|
disease |
BEFREE |
Presence of anti-IFN antibodies was assessed at baseline and at 3 and 6 months post-treatment in 323 CHB patients treated with PEG-IFN for 1 year.
|
24296674 |
2014 |
Complete atrioventricular block
|
0.100 |
Biomarker
|
disease |
BEFREE |
IL28-B polymorphisms are related to different response in the treatment of CHB HBeAg-negative with PEG-IFN, and the E genotype is a novel negative predictive factor.
|
24316030 |
2014 |
Complete atrioventricular block
|
0.100 |
Biomarker
|
disease |
BEFREE |
Understanding these factors can help determine personalized PEG-IFN therapy for CHB patients.
|
24373087 |
2014 |
Complete atrioventricular block
|
0.100 |
Biomarker
|
disease |
BEFREE |
However, the limited efficacy is the main factor restricting the use of PEG-IFNα in CHB and therefore identifying the predictors of response is of great clinical importance.
|
24373089 |
2014 |
Complete atrioventricular block
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
The MOV10, A3G, and IFN-α mRNA levels in CHB group was significantly lower than those in the control group (P<0.01, P<0.05, P<0.01, respectively).
|
24871977 |
2014 |
Complete atrioventricular block
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
This retrospective analysis compared the treatment efficacy of PEG-IFN-α2b alone in 55 HBeAg-positive CHB patients with different baseline HBsAg levels.
|
25009392 |
2014 |
Complete atrioventricular block
|
0.100 |
Biomarker
|
disease |
BEFREE |
The highest response rate to IFN treatment was found in patients infected with HBV genotype A, followed by HBV genotypes B, C, and D. The long-term effect of IFN-α on CHB has not yet been elucidated.
|
25309065 |
2014 |
Complete atrioventricular block
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Furthermore, IFN-α boosted the expression of Mx2 and cytokine genes in γδT cells from CHB patients in vitro.
|
25774808 |
2015 |
Complete atrioventricular block
|
0.100 |
Biomarker
|
disease |
BEFREE |
We aimed to investigate the effect of Peg-IFN therapy in treatment-experienced CHB patients.
|
25835020 |
2015 |
Complete atrioventricular block
|
0.100 |
Biomarker
|
disease |
BEFREE |
In summary, ss469415590 genotypes were not associated with response to PEG-IFN in Thai patients with HBeAg-positive and HBeAg-negative CHB.
|
26225703 |
2015 |
Complete atrioventricular block
|
0.100 |
Biomarker
|
disease |
BEFREE |
Data from this study demonstrated for the first time that IP-10 polymorphism is independently associated with treatment response to PEG-IFN in patients with HBeAg-positive CHB.
|
26376789 |
2016 |
Complete atrioventricular block
|
0.100 |
Biomarker
|
disease |
BEFREE |
Toll-IL1 receptor-mediated innate immune responses vary across HBV genotype and predict treatment response to pegylated-IFN in HBeAg-positive CHB patients.
|
26436722 |
2016 |
Complete atrioventricular block
|
0.100 |
Biomarker
|
disease |
BEFREE |
The aim of this study was to investigate possible involvement of estrogen receptor α (ESR1) in responding to pegylated interferon alpha-2a (PEG IFNα-2a) therapy in chronic hepatitis B (CHB) patients.
|
26485345 |
2016 |
Complete atrioventricular block
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Compared to the rs7574865 GT/TT genotype, the GG genotype (a risk factor of CHB and hepatitis B virus-related hepatocellular carcinoma) was significantly associated with a reduced SVR rate in both patients who received IFNα-2b therapy (21.1% versus 37.2%, P = 0.01) and those who received pegylated IFNα-2a therapy (18.0% versus 41.2%, P = 9.74 × 10(-5) ).
|
26704347 |
2016 |
Complete atrioventricular block
|
0.100 |
Biomarker
|
disease |
BEFREE |
Even after stimulation by TLR agonists, no change was found in IFN-α production in CHB patients.
|
27658394 |
2016 |
Complete atrioventricular block
|
0.100 |
Biomarker
|
disease |
BEFREE |
However, only a minority of chronic hepatitis B (CHB) patients generate a sustained response after treatment with recombinant IFNα.
|
27839836 |
2017 |
Complete atrioventricular block
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
In this study, we aimed to investigate the expression and function of TLR8 in peripheral blood mononuclear cells (PBMCs) of chronic hepatitis B (CHB) patients and its alteration during peg-IFN-α-2a therapy.
|
28236535 |
2017 |